The Biomarkers for Preterm Birth Study—A prospective observational study comparing the impact of vaginal biomarkers on clinical practice when used in women with symptoms of preterm labor

Abstract

The use of quantitative fetal fibronectin (admission threshold ≥200 ng/mL) has the potential to reduce the rate of antenatal admissions for women with symptoms of preterm labor without compromising use of antenatal interventions that improve outcomes for babies born preterm.